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Background: The multifunctional glycoprotein clusterin has been associated with late-onset Alzheimer’s disease
(AD). Further investigation to define the role of clusterin in AD phenotypes would be aided by the development of
techniques to quantify level, potential post-translational modifications, and isoforms of clusterin. We have
developed a quantitative technique based on multiple reaction monitoring (MRM) mass spectrometry to measure
clusterin in human postmortem brain tissues.
Results: A stable isotope-labeled concatenated peptide (QconCAT) bearing selected peptides from clusterin was
expressed with an in vitro translation system and purified. This clusterin QconCAT was validated for use as an
internal standard for clusterin quantification using MRM mass spectrometry. Measurements were performed on the
human postmortem frontal and temporal cortex from control and severe AD cases. During brain tissues processing,
1% SDS was used in the homogenization buffer to preserve potential post-translational modifications of clusterin.
However, MRM quantifications in the brain did not suggest phosphorylation of Thr393, Ser394, and Ser396 residues
reported for clusterin in serum. MRM quantifications in the frontal cortex demonstrated significantly higher
(P< 0.01) level of clusterin in severe AD group (39.1 ± 9.1 pmol/mg tissue protein) in comparison to control group
(25.4 ± 4.4 pmol/mg tissue protein). In the temporal cortex, the clusterin levels were not significantly different,
29.0 ± 7.9 pmol/mg tissue protein and 28.0 ± 8.4 pmol/mg tissue protein in control and severe AD groups,
respectively.
Conclusions: The proposed protocol is a universal quantitative technique to assess expression level of clusterin. It is
expected that application of this protocol to quantification of various clusterin isoforms and potential
post-translational modifications will be helpful in addressing the role of clusterin in AD.
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Genome-wide associated studies have linked the CLU
gene with the risk of developing late-onset Alzheimer’s
disease (AD) [1,2]. CLU encodes clusterin, a multifunc-
tional glycoprotein, whose involvement in AD has been
discussed since increased clusterin expression in AD
hippocampus was first reported two decades ago [3].
Subsequent Western blot and ELISA quantifications
pointed to increased levels of clusterin in AD hippocam-
pus and in frontal cortex [4], cerebrospinal fluid [5], and
plasma [6]. However, other Western blot studies* Correspondence: iturko@umd.edu
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reproduction in any medium, provided the ordemonstrated that levels of clusterin did not differ sig-
nificantly between control and AD cases in the frontal
cortex, temporal cortex, or thalamus in postmortem
human brain [7,8]. The explanation for these differences
is unclear, but might originate from the variety of clus-
terin antibodies used and availability of clusterin epi-
topes in the different biological samples examined. The
challenge of understanding the role of clusterin in AD
goes beyond the quantification of protein levels. Clus-
terin has alternative splicing variants, single nucleotide
polymorphisms, and post-translational modifications
[9,10], which are difficult to ascertain with immuno-
logical methods and likely associated with development
of AD. Overall, the availability of a reliable quantitative
approach is needed to facilitate clarification of the role
of clusterin in AD.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(MRM) mass spectrometry to proteomics has greatly
enhanced the selectivity and accuracy of protein quanti-
fication. Absolute quantification using MRM assay relies
on isotope-labeled internal standards, which can be pep-
tides [11], concatenated peptides (QconCAT) [12], or
full-length proteins [13]. However, utilization of any of
these internal standards has limitations. Isotope-labeled
peptides provide the most high-throughput analysis, al-
though have the highest chance of serious quantitative
discrepancies between analyte and standard. Isotope-
labeled full-length proteins are perfectly quantitative as
internal standards, but do not support high-throughput
analysis due to poor availability. QconCATs have a
strong potential to be perfectly quantitative and support
high-throughput analysis at the same time [14,15].
QconCATs are similar to analyte proteins, but not
identical. Potentially, this can result in incomplete prote-
olysis of either the QconCATs or the analyte proteins
and therefore affect quantification. There are two main
determinants of the rate of proteolysis. First is the com-
position of amino acid residues around the cleavage site.
The second is the tight folding of some proteins that
makes them intrinsically resistant to proteolysis. We
addressed these issues by (i) incorporating into the
QconCATs the original flanking sequences from the pro-
teins that surround the tryptic fragments (Q-peptides) to
create an identical amino acid composition around the
cleavage site, and (ii) initial treatment of biological sam-
ples with a SDS-containing buffer to completely unfold
proteins. SDS in the homogenization buffer has the
added advantage of preserving post-translational modifi-
cations that may be present in target proteins. The final
optimized protocol was used to assess the levels of clus-
terin and levels of potential clusterin phosphorylation in
the specimens of human brain from control and severe
AD donors. The data obtained expand our understand-
ing of the role(s) clusterin may play in AD.
Results and discussion
Flanking regions for Q-peptides
Often, the Q-peptides in the QconCAT are directly adja-
cent to each other. Thus, the flanking regions of Q-
peptides in the standard and analyte are different and
proteolysis may occur at a different rate for the Qcon-
CAT and analyte. To avoid potential quantitative dis-
crepancy, the incorporation of native flanking sequences
into the QconCATs was first proposed by Kito et al. [16]
and further used by Nanavati et al. [14]. At the same
time, evaluation of QconCATs without flanking
sequences demonstrated that the digestion protocol had
a significant impact on final quantification [17].
Figure 1A illustrates the design of our QconCAT for
clusterin with five Q-peptides carrying 6-amino acidlong extensions from their natural sequences on both
sides of the Q-peptides. This QconCAT was expressed
as an isotope-labeled protein and purified using a C-
terminal His6-tag (Figure 1B). The His6-tag is separated
from the last Q-peptide by the flanking sequence specific
for that Q-peptide and therefore will not affect the rate
of proteolytic release. Additionally, the presence of flank-
ing sequences eliminates concerns about dibasic cleavage
sites and acidic residues at P2’ position and allows for
greater flexibility in QconCAT design.
Optimal MRM transitions for Q-peptides were experi-
mentally selected from analysis of clusterin QconCAT
tryptic digestion. These transitions were then used to de-
termine the level of stable isotope incorporation in the
clusterin QconCAT. Signals from Q2- and Q3-peptides
were low and these two peptides were not used for fur-
ther quantifications. Figure 1C shows representative
extracted ion chromatograms for Q1, Q4, and Q5 pep-
tides. It is evident that both light and heavy versions of
the peptides are present. This is presumably due to con-
taminating unlabeled Arg or Lys amino acids, or synthe-
sis, in the in vitro kit. The isotope incorporation factor,
α, is calculated as the ratio of the area of the labeled
peak to the sum of the unlabeled and labeled peaks. The
two strongest transitions per peptide were used to calcu-
late isotope incorporation for each peptide. Combined
data for these three peptides resulted in a final value of
0.75 ± 0.02. A single point calibration was used to assign
a concentration value based on the following formula:








tissue protein mgð Þ
where A is the analyte peak area, S is the standard peak
area, and α is the isotope incorporation factor. The
equation functions to shift the light component of the Q
peptide from the analyte peak area to the standard peak
area proportionally based on the isotope incorporation
factor.
The MRM transitions used for all following quantifica-
tions are summarized in Table 1.
SDS-containing buffer for sample processing
QconCATs are artificial proteins, which are not expected
to be folded into higher order structures. Nevertheless,
on the level of QconCAT design, we selected only those
peptides from clusterin which are not involved in β-
sheet formation in the native clusterin to avoid a poten-
tial resistance to proteolysis. To ensure full unfolding of
the native clusterin and equal proteolytic rates for ana-
lyte (native clusterin) and internal standard (clusterin
QconCAT), 25 mM NH4HCO3 containing 1% (m/V)
Figure 1 Design, expression, and characterization of clusterin QconCAT. (A). Clusterin QconCAT includes five Q peptides (shown in green)
with 6-amino acid long flanking regions (shown in yellow) concatenated into the sequence with N-terminal Met and C-terminal His6-tag. (B)
Coomassie R250 stained clusterin QconCAT after 15% polyacrylamide gel separation. (C) Stable isotope incorporation into the clusterin. MRM
spectra for two representative transitions per Q1, Q4, and Q5 peptides are shown. The pair transitions for light (unlabeled) and heavy (labeled)
form of each Q peptide are color coordinated. Isotope incorporation factor for clusterin QconCAT was calculated based on combined data for all
three peptides and presented as mean± SD.
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processing. In addition, SDS-containing buffer for bio-
logical sample processing immediately terminates any
enzymatic reactions that can change the levels of present
post-translational modifications. After supplementation
with QconCAT and alkylation of Cys residues, samples
were precipitated with chloroform/methanol to remove
SDS, biological lipids, and by-products of alkylation. The
resulting pellet of pure and fully unfolded proteins was
further proteolysed and analyzed by MRM.
Validation of proteolytic digestion
To determine the completeness of digestion, we per-
formed trypsin digestions of human recombinant clus-
terin (purity > 95%, ProSpec-Tany Technogene, Ness
Ziona, Israel) and clusterin QconCAT mixed in different
ratios. Table 2 demonstrates that, based on three pep-
tides and two different ratios, the average difference be-
tween mixed concentrations and actually measured isTable 1 Peptides and MRM transitions used for the quantifica
Peptides Precursor
ASSIIDELFQDR (Q1 ,light) 697.35 (+2)
ASSIIDELFQDR (Q1 ,heavy) 702.36 (+2)
ELDESLQVAER (Q4 ,light) 644.82 (+2)
ELDESLQVAER (Q4 ,heavy) 649.83 (+2)
VTTVASHTSDSDVPSGVTEVVVK (Q5 ,light) 772.06 (+3)
VTTVASHTSDSDVPSGVTEVVVK (Q5 ,heavy) 774.74 (+3)
[13C6,
15 N2]-Lys and [
13C6,
15 N4]-Arg in labeled peptides are shown in bold. For MRM
ions are shown in parentheses.approximately 16%. In addition to the rate of proteolysis,
this combined error also includes the errors generated
by mixing of clusterins and the MRM assay itself. Over-
all, this difference is very acceptable for quantification
and the data confirm that proteolytic digestion of our
clusterin QconCAT accurately reproduces proteolytic di-
gestion of native full-length clusterin.
Quantification of clusterin
The methodological improvements described above
demonstrated that flanking sequences for Q-peptides in
QconCAT in combination with full-unfolding of native
proteins in 1% SDS prevent potential inconsistency in the
tryptic digestion and reduce the bias in quantification. To
finalize the protocol for clusterin quantification in brain
tissues, the dynamic range and limit of quantification
(LOQ) were determined in temporal cortex homogenates.
The standard curves were generated for Q1-, Q4-, and Q5-
peptides by mixing different concentrations of labeledtion of clusterin
MRM transitions (m/z)
Product
678.40 (y5,+1) 922.43 (y7,+1) 1035.51 (y8,+1)
688.40 (y5,+1) 932.43 (y7,+1) 1045.52 (y8,+1)
602.30 (y5,+1) 802.44 (y7,+1) 1046.51 (y9,+1)
612.30 (y5,+1) 812.45 (y7,+1) 1056.52 (y9,+1)
507.80 (y10,+2) 773.48 (y7,+1) 1014.58 (y10,+1)
511.80 (y10,+2) 781.49 (y7,+1) 1022.60 (y10,+1)
transitions, charge for precursor ions, and, and the type and charge for product




ASSIIDELFQDR (Q1) 1.0 1.2 ± 0.1
2.0 2.4 ± 0.2
ELDESLQVAER (Q4) 1.0 1.3 ± 0.2
2.0 1.9 ± 0.3
VTTVASHTSDSDVPSGVTEVVVK (Q5) 1.0 1.2 ± 0.2
2.0 2.4 ± 0.3
consensus 1.50 (100%) 1.73 (116%)
The measurements were performed for three experimental replicates by
monitoring three transitions per individual peptide and presented as
mean ± SD. For consensus, the mean measured ratio is presented as a
percentile of mean mixed ratio.
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0.2 mg of temporal cortex homogenate. The data were
plotted for every individual transition and showed linearity
and low scatter. Figure 2 shows a representative standard
curve for each Q peptide. LOQ was defined as the lowest
standard point of the curve that could be measured with a
coefficient of variance less than 20%. The LOQ was 3
pmol/mg of tissue protein for Q1- and Q5-peptides. The
measurements based on Q4-peptide were less sensitive
with LOQ equal to 10 pmol/mg of tissue protein. For this
reason, Q4-peptide was not used for the following quanti-
fications in the human brain.
Clusterin was quantified (summarized in Table 3) in
human frontal and temporal cortex brain samples
obtained from two groups of donors, control with no
or minimal AD changes (clinical dementia rating 0)
and severe AD cases (clinical dementia rating 3) [for
demographic information of the donors, see Additional
file 1]. Notably, the measurements based on the
Q1-peptide (ASSIIDELFQDR) and those based on
Q5-peptide (VTTVASHTSDSDVPSGVTEVVVK) are
similar. Phosphorylation of Thr393, Ser394, or Ser396 in
VTTVASHTSDSDVPSGVTEVVVK has been reported
for clusterin present in serum [10]. Our protocol for
sample processing includes tissue homogenization inFigure 2 Representative standard curves for Q1, Q4, and Q5 peptides.
plotted versus suplemented clusterin QconCAT amount for each Q peptide
644.82/602.30 and 649.83/612.30; Q5-t1 is 772.06/507.80 and 774.74/511.80.the presence of 1% SDS which should prevent loss of
post-translational modifications. If any modifications
were present in Q5, the measurements based on Q5
would be lower (than based on Q1) proportionally to
the level of modification. However, we did not observe
a statistically significant difference between quantifica-
tions based on Q1 and Q5. This may point to a very
low level of Thr393, Ser394, or Ser396 phosphorylation
in the brain, if any.
The second important observation is that the level of
clusterin in frontal cortex is significantly higher
(P < 0.01) in severe AD (39.1 ± 9.1 pmol/mg tissue pro-
tein) in comparison to control (25.4 ± 4.4 pmol/mg tissue
protein) while the clusterin levels in the temporal cortex
are not significantly different, 29.0 ± 7.9 pmol/mg tissue
protein and 28.0 ± 8.4 pmol/mg tissue protein in control
and severe AD groups, respectively. These quantifica-
tions point to a selective increase of clusterin level in the
specific region of AD brain.
Conclusions
We have developed an antibody-free protocol for clus-
terin quantification in tissue samples. The protocol
includes tissue homogenization in 1% SDS that will be
helpful in discovery and validation of clusterin isoforms
and post-translational modifications. The subsequent
chloroform/methanol precipitation is a simple approach
to remove SDS before trypsinolysis and MRM. In
addition, we have used isotope-labeled QconCAT with
original flanking regions for every Q-peptide and
demonstrated that this internal standard entirely
matched to full-length clusterin in the MRM quantita-
tive assay. Subsequent measurements of clusterin in
frontal and temporal cortex from control and severe AD
donors showed that the proposed protocol can be used
to address the role of clusterin in AD.
Methods
Materials
Expressway cell-free E.coli expression system was from
Invitrogen (Carlsbad, CA). L-[13C6,
15 N2]lysine andThe area ratio of heavy to light peaks for a selected transition was
. Transitions: Q1-t3 is 697.35/1035.51 and 702.36/1045.52; Q4-t1 is
Table 3 Quantification of clusterin in the human brain tissues
Clusterin, pmol/mg tissue protein
Frontal cortex Temporal cortex
Control Severe AD Control Severe AD
ASSIIDELFQDR (Q1) 26.0 ± 4.2 39.6 ± 9.0 29.5 ± 7.4 24.2 ± 8.5
VTTVASHTSDSDVPSGVTEVVVK (Q5) 24.8 ± 4.7 38.6 ± 9.3 27.8 ± 7.9 29.3 ± 7.7
consensus 25.4 ± 4.4 39.1 ± 9.1 29.0 ± 7.9 28.0 ± 8.4
Each control and severe AD group includes six human donors. The concentration was calculated for three experimental replicates by monitoring three transitions
per individual peptide and presented as mean ± SD. The monitored transitions are summarized in Table 1. The reported phosphorylated Thr and Ser residues [10]
are underlined. For the consensus, the data for both peptides were combined and presented as mean ± SD. Clusterin concentrations in frontal cortex were
significantly different (P< 0.01) using a t test comparison for the control and severe AD groups, whereas clusterin concentrations in temporal cortex were not
significantly different.
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15N4]arginine (>95% purity) were from Spectral
Stable Isotopes (Columbia, MD). The DC Protein Assay
kit was from Bio-Rad Laboratories (Hercules, CA). Se-
quencing grade modified trypsin was obtained from Pro-
mega Corp. (Madison, WI). Recombinant human
clusterin (purity > 95%) was from ProSpec-Tany Techno-
gene, Ness Ziona, Israel. All other chemicals were pur-
chased from Sigma-Aldrich (St. Louis, MO).
Design, expression and purification of clusterin QconCAT





by Integrated DNA Technologies (Coralville, Iowa). The
underlined segments represent the signature proteotypic
peptides of clusterin (Q-peptides). The synthetic clus-
terin gene was cloned into the pEXP5CT/TOPO expres-
sion vector in-frame to the C-terminal His6-tag. Stable
isotope-labeled clusterin QconCAT was expressed using




15 N4]arginine were added to the amino acid mix-
ture to replace unlabeled lysine and arginine. After
in vitro translation, the labeled clusterin QconCAT was
purified by nickel-nitrilotriacetic acid resin in batch
mode (Qiagen, Valencia, CA). Finally the purified Qcon-
CAT was loaded onto the SpinTrap G-25 spin column
(GE Healthcare, Waukesha, WI) to exchange buffer into
25 mM NH4HCO3 with 1% (m/V) SDS. The protein
concentration of clusterin QconCAT was measured in
the presence of 1% (m/V) SDS using the DC protein
Assay kit and bovine serum albumin as a standard. The
final clusterin QconCAT was aliquoted and kept frozen
at −80°C.
Human tissues
Samples of frontal cortex were received from the Wash-
ington University School of Medicine Alzheimer’s Dis-
ease Research Center. Samples of temporal cortex wereobtained from the Alzheimer's Disease Center, Boston
University. All brain specimens were collected from de-
identified donors following informed consent of the re-
spective families.
Processing of samples
The minced brain tissue was placed in 25 mM
NH4HCO3/1% (m/V) SDS and homogenized by sonic-
ation at 30 W using five 10 s continuous cycles (Sonica-
tor 3000, Misonix Inc., Farmingdale, NY). The
homogenate was centrifuged at 2000 g for 5 min to re-
move tissue debris. The supernatant was used to meas-
ure total protein concentration in the presence of 1%
SDS using the DC protein Assay kit and bovine serum
albumin as a standard. The supernatant was then ali-
quoted 0.2 mg of total tissue protein per tube and kept
frozen at −80°C. During the following experiments, sam-
ples of 0.2 mg of total tissue protein were supplemented
with 20 mM DTT and various amounts of labeled clus-
terin QconCAT, ranging from 0.1 pmol to 10 pmol per
sample. The mixture was incubated at room temperature
for 60 min to allow reduction of cysteines and was then
treated with 50 mM iodoacetamide for another 60 min.
Alkylated samples were precipitated with chloroform/
methanol [18]. The protein pellets obtained were soni-
cated in 100 μL of 25 mM NH4HCO3 and treated with
trypsin for 15 h at 37°C. The substrate/trypsin ratio was
50:1 (m/m). After trypsinolysis, the samples were dried
using a vacuum centrifuge (Vacufuge, Eppendorf AG,
Hamburg, Germany).
LC-MS/MS analysis
Instrumental analyses were performed on a hybrid triple
quadrupole/linear ion trap mass spectrometer (4000
QTRAP, ABI/MDS-Sciex) coupled to an Eksigent
nanoLC-2D system (Dublin, CA). Separation of peptides
was performed with an Eksigent cHiPLC- nanoflex sys-
tem equipped with a nano cHiPLC column, 15 cm x
75 μm, packed with ReproSil-Pur C18-AQ, 3 μm
(Dr. Maisch, Germany). Peptides were eluted over a
29 min-gradient from 15% to 35% acetonitrile,
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min. The column effluent was continuously directed into
the nanospray source of the mass spectrometer. All ac-
quisition methods used the following parameters: an ion
spray voltage of 2200 V, curtain gas of 105 kPa (15 psi),
source gas of 140 kPa (20 psi), interface heating
temperature of 170°C, declustering potential of 76 V for
+2 precursor ions and 65 V for +3 precursor ions, colli-
sion energy of 30 V for +2 precursor ions and 22 V for
+3 precursor ions, and collision cell exit potential of
16 V for +2 precursor ions and 13 V for +3 precursor
ions. The dwell time for all transitions was 40 ms.
Quantitative analysis and validation
The initial list of MRM transitions was selected as
described [19] and was experimentally screened for the
three most intensive transitions per peptide. These tran-
sitions were further used for quantification. The relative
ratios of the three transitions monitored in the 25 mM
NH4HCO3 for labeled clusterin QconCAT were similar
to those observed by spiking labeled clusterin QconCAT
into the biological samples. This indicated no significant
interference for the quantification based on selected
transitions. The identities of the measured peptides were
confirmed based on the retention time of the three
MRM peaks from a given peptide and the ratio among
the three MRM peaks. The reported value for each
group was the mean and SD of each biological replicate
using all peptide transitions.
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